Accolade (NASDAQ:ACCD) Releases Earnings Results

Accolade (NASDAQ:ACCD) issued its quarterly earnings data on Thursday. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01, Briefing.com reports. The firm had revenue of $124.80 million during the quarter, compared to the consensus estimate of $123.91 million. Accolade had a negative net margin of 31.59% and a negative return on equity of 27.27%. The company’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.42) earnings per share. Accolade updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Accolade Stock Performance

Accolade stock traded down $1.43 during trading on Friday, reaching $7.76. The company had a trading volume of 955,055 shares, compared to its average volume of 721,127. The firm’s 50-day simple moving average is $9.75 and its 200 day simple moving average is $9.92. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.48. Accolade has a 52 week low of $6.33 and a 52 week high of $17.00. The firm has a market capitalization of $600.70 million, a price-to-earnings ratio of -4.81 and a beta of 2.08.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Raymond James lifted their price objective on Accolade from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 9th. Piper Sandler raised their target price on shares of Accolade from $12.00 to $15.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 9th. Wells Fargo & Company boosted their price target on shares of Accolade from $10.00 to $12.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 9th. Needham & Company LLC lowered their price objective on shares of Accolade from $17.00 to $13.00 and set a “buy” rating for the company in a report on Friday. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Accolade in a research report on Monday, February 26th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Accolade has an average rating of “Moderate Buy” and a consensus target price of $14.80.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.